ReviewBreast cancer research : BCR2026
Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside.
Review in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAcquired therapy resistance, particularly endocrine resistance in estrogen receptor-positive (ER +) breast cancer, remains a major clinical challenge. Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic paradigm with the potential to overcome resistance by degrading target proteins. This study provides a comprehensive landscape analysis of PROTACs in breast cancer, synthesizing research trends and clinical trial progress to map the path from discovery to application.
methodsWe conducted a dual-perspective analysis. Bibliometric data from 350 publications (Web of Science Core Collection) were analyzed to delineate the research evolution, collaboration networks, and target focus. Concurrently, 30 clinical trials registered on ClinicalTrials.gov were systematically reviewed to evaluate the clinical translational stage, target distribution, and safety profiles of PROTACs in breast cancer.
resultsResearch output has grown exponentially since 2016, led by China and the United States. The estrogen receptor (ER) is the predominant target in both basic and clinical research. Clinical development is advancing rapidly, with the ER degrader ARV-471 reaching phase III trials. In patients with ER + /HER2 - advanced breast cancer and ESR1 mutations, ARV-471 demonstrated a median progression-free survival of 5.0 months, doubling that achieved with fulvestrant (2.1 months). While fatigue and nausea are common adverse events, the overall safety profile appears manageable. However, clinical exploration remains highly concentrated on ER + disease, with limited progress in other subtypes such as HER2 + and triple-negative breast cancer.
conclusionsPROTACs, especially ER degraders, suggest a potential strategy for addressing endocrine resistance in advanced ER + breast cancer, as reflected in encouraging preliminary clinical data. This integrated analysis highlights the rapid translation of this technology while underscoring the critical need to expand target scope, address inherent resistance mechanisms, and broaden applications to other breast cancer subtypes. Our article synthesizes current knowledge and trial landscape, thereby providing a consolidated foundation to inform future research and clinical development of PROTACs in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.